Subscribe To
GLTO / All You Need to Know About Galecto, Inc. (GLTO) Rating Upgrade to Strong Buy
GLTO News
By GlobeNewsWire
August 31, 2023
Galecto to Present at Investor Conferences in September
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology fo more_horizontal
By Zacks Investment Research
August 16, 2023
Galecto (GLTO) Down 71% as Lung Disease Candidate Fails
Galecto's (GLTO) shares fall as the mid-stage study of GB0139 to treat idiopathic pulmonary fibrosis fails to meet its primary endpoint. more_horizontal
By Market Watch
August 15, 2023
Galecto shares drop 65% as biotech halts development of lung-disease treatment
Shares of Galecto Inc. GLTO dropped 65% in premarket trading Tuesday after the biotech company said it would drop an investigational treatment for idi more_horizontal
By Reuters
August 15, 2023
Galecto to discontinue development of lung disease treatment
Drug developer Galecto said on Tuesday it will discontinue development of its lung disease treatment after it failed to meet its primary goal in a mid more_horizontal
By GuruFocus
July 27, 2023
ORBIMED ADVISORS LLC Reduces Stake in Galecto Inc
On July 25, 2023, ORBIMED ADVISORS LLC (Trades, Portfolio), a renowned investment firm, reduced its stake in Galecto Inc, a clinical-stage biotechnolo more_horizontal
By 24/7 Wall Street
April 10, 2023
Orbimed Advisors Now Owns 10.5% of Galecto
Fintel reports that Orbimed Advisors has filed a 13D/A form with the SEC disclosing ownership of 2.70MM shares of Galecto Inc (GLTO). more_horizontal
By Zacks Investment Research
November 11, 2022
All You Need to Know About Galecto, Inc. (GLTO) Rating Upgrade to Strong Buy
Galecto, Inc. (GLTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong more_horizontal